Scholar Rock initiates Phase 2 EMBRAZE obesity trial; SRK-439 preclinical data shows superiority over anti-ActRII

Scholar Rock Holding Corp

Phase 2 EMBRAZE proof-of-concept trial initiated for apitegromab in obesity, targeting 100 subjects on GLP-1 RA; primary data expected mid-2025.
Preclinical head-to-head: SRK-439 at 1 mg/kg preserved lean mass equivalent to anti-ActRII at 20 mg/kg; all doses showed superiority.
Loan Amendment No. 4 extends interest-only period to May 2025, modifies milestones for $25M additional tranche available through Dec 2024.
SRK-439 attenuated lean mass loss to 4.2% at 10 mg/kg vs. 14.1% with IgG control + semaglutide in DIO mice.
Company hosts Investor Day; anticipates IND filing for SRK-439 in 2025 after EMBRAZE results.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.